These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 12117075

  • 1. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.
    Parker LM.
    Clin Ther; 2002; 24 Suppl C():C43-57. PubMed ID: 12117075
    [Abstract] [Full Text] [Related]

  • 2. Evolving uses of hormonal agents for breast cancer therapy.
    Cummings FJ.
    Clin Ther; 2002; 24 Suppl C():C3-25. PubMed ID: 12117074
    [Abstract] [Full Text] [Related]

  • 3. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer.
    Costantino J.
    Clin Ther; 2002; 24 Suppl C():C26-42. PubMed ID: 12117073
    [Abstract] [Full Text] [Related]

  • 4. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ, Johnston SR, Howell A.
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [Abstract] [Full Text] [Related]

  • 5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 6. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K, Curran MP, Plosker GL.
    Drugs; 2004 Aug; 64(6):633-48. PubMed ID: 15018596
    [Abstract] [Full Text] [Related]

  • 7. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A, Howell SJ, Clarke R, Anderson E.
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [Abstract] [Full Text] [Related]

  • 8. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
    Ohno S.
    Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU.
    Oncologist; 2003 Aug; 8(4):335-41. PubMed ID: 12897330
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.